24 April 2007
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director, President and Chief Executive Officer

SymBio Pharmaceuticals Signs Agreement with Astellas Deutschland GmbH:
In-Licenses Rights to”Bendamustine” in Key Asia-Pacific Rim Countries
SymBio Pharmaceuticals Limited recently signed a definitive License Agreement withAstellas Deutschland GmbH (Munich, Germany), a subsidiary of Astellas Pharma Inc. (Tokyo,Japan), for exclusive rights to development and commercialization of the antineoplastic agent,
SyB L-0501（”bendamustine hydrochloride”）, in China, Korea, Taiwan, and Singapore.
SymBio is currently conducting clinical studies on SyB L-0501, in Non-Hodgkin’s Lymphoma
patients in Japan. This new Agreement signifies the intention of SymBio Pharmaceuticals
and Astellas Deutschland GmbH to further expand SyB L-0501development into otherAsia-Pacific Rim countries.
Significant growth in medical needs, and an increasing demand for higher quality therapeuticoptions, are expected in key Asia-Pacific markets currently undergoing rapid economic
development. Further expansion of business activities in addressing these anticipatedneeds, is one of SymBio’s most important strategic initiatives. Hence, SymBio establishedan Asia-Pacific Office on April 1st, 2007 that reports directly to the President and CEO, andwill divert significant resources into building its presence within the region.
SymBio Pharmaceuticals will establish a stronger presence across the Asia-Pacific region
with the development and commercialization of SyB L-0501 and SyB‐0701（”AB1001”）, a
transdermal patch in-licensed from Abeille Pharmaceuticals Inc. last March, in key
Asia-Pacific Rim countries. In line with its ongoing Business Development strategy, SymBio
Pharmaceuticals intends to continue placing a high priority on in-licensing rights for Japanand other growing Asian markets.
Similar to the situation existing in Japan, the therapeutic areas of oncology, hematology, andauto-immune disease are emerging as areas of unmet medical needs across the Asia-Pacificregion. In pursuit of its corporate mission, SymBio will place significant effort and resources
into delivering effective therapies to patients in need across the Asia Pacific region, as rapidly
as possible.

【Company Profile】
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals’ focus is on oncology/hematology and autoimmune disease
therapies. Established in March 2005 by Fuminori Yoshida, who previously served as both
Corporate Vice President of Amgen Inc. and president of Amgen Japan, SymBio
Pharmaceuticals’ underlying corporate philosophy is “delivering hope to patients in need,”
and the company aims to address unmet medical needs of patients in Japan by cultivating amutually beneficial or symbiotic relationship among physicians, scientists, regulatoryagencies, and investors. SymBio Pharmaceuticals core philosophy is that profitability andsocially responsibility as a pharmaceutical enterprise can go hand in hand, and need not be
mutually exclusive.
About Astellas Deutschland GmbH:
Astellas Deutschland GmbH, Munich is a German subsidiary of Astellas Pharma Inc., basedin Tokyo, Japan. In April 2005, Astellas Pharma Inc. was created through the merger of
Yamanouchi Pharmaceutical Co., Ltd and Fujisawa Pharmaceutical Co., Ltd. Theorganization is committed to becoming a global pharmaceutical company by combining
outstanding R&D and marketing capabilities with international expertise, thereby sustaining aphenomenal growth rate and strong presence within the world pharmaceutical market.

For further information, please contact:
SymBio Pharmaceuticals Limited
Kyoko Seki,
Corporate Officer, Director Public Relations and Investor Relations
Tel: +81 (0) 3 5472 1123
E-mail: kseki@symbiosis.co.jp
URL:http://www.symbiosis.co.jp（Note）In December 2005, SymBio entered into a License Agreement with Astellas Pharma GmbH
(Munich,Germany) for the exclusive development and distribution of “Bendamustine” for theJapanese market. This anticancer drug has been used extensively in Germany, under thetrade name “Ribomustin®,” for the treatment of non-Hodgkin's lymphoma. For Japan,
SymBio is now conducting a phase I clinical trial of SyB L-0501 at four facilities, with patients
who have relapsed/refractory indolent non-Hodgkin's lymphoma. Enrollment of a total ofnine patients was completed earlier than scheduled, and the phase I clinical trial, including
data analysis, should be completed by the end of August this year.